Printer Friendly

Sankyo Ceases Clinical Studies of Pactimibe, Investigational Drug for ASCVD.

Tokyo, Japan, Oct 28, 2005 - (JCNN) - Daiichi Sankyo announced on October 26 that its subsidiary Sankyo has decided to cease its ongoing clinical studies of pactimibe (CS-505), an investigational drug for the treatment of arteriosclerotic cardiovascular disease (ASCVD). The agent pactimibe is an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.

The decision was made because the company could not obtain favorable results from the current phase II clinical study named the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) study conducted in the US.

Detailed results of the ACTIVATE study will be presented at the 2005 American Heart Association's Scientific Sessions to be held in Texas on November 15.

Source: JCN

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Oct 31, 2005
Previous Article:Kagome to Introduce New Collagen Yogurt Drink.
Next Article:Novartis Pharma to Spin off Its Nutrition Business in January.

Related Articles
Out of the laboratory and into the bathroom cabinet: designing and implementing clinical trials. (Clinical Trials).
The salvage therapy II think tank.
Proof of concept studies/translational research; new hypotheses: (a personal take on Panel 2. Discussion leader: Kimberly Struble).
Sankyo Licenses Cardiovascular Disease Drug Candidate KAI-9803 from KAI Pharmaceuticals.
Sankyo to Supply Hyperlipidemia Drug Pravastatin in US.
Chugai Files NDA for an Anti-Tumor Agent, Erlotinib (Epidermal Growth Factor Receptor (EGFR/HER1) Tyrosine Kinase Inhibitor).
Sankyo to Manufacture, Distribute Olmetic Antihypertensive Drug in China.
Ajinomoto, Sankyo in Joint Development, Manufacture and Marketing of AJD101, New Diabetes Drug.
Daiichi Sankyo Announces Completion of Phase I Trial on the Anti-influenza Drug CS-8958.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |